---
layout: default
title: Fluorouracil
parent: 僅模型預測 (L5)
nav_order: 147
evidence_level: L5
indication_count: 10
---

# Fluorouracil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluorouracil: From Gastrointestinal Cancer to Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina

## One-Sentence Summary

Fluorouracil (5-FU) is a classic fluoropyrimidine antimetabolite that has served as a cornerstone chemotherapy agent for colorectal, gastric, and other gastrointestinal cancers for decades.
The TxGNN model predicts it may be effective for **Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina**,
however, with **0 clinical trials** and **0 publications** directly supporting this specific indication, the entire evidence base rests on model prediction alone.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available from Philippines registry (no registered products) |
| Predicted New Indication | Botryoid-Type Embryonal Rhabdomyosarcoma of the Vagina |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacology, Fluorouracil (5-FU) is a fluoropyrimidine antimetabolite that inhibits thymidylate synthase (TS), a key enzyme responsible for synthesizing thymidine nucleotides required for DNA replication. By blocking TS, 5-FU starves rapidly proliferating cells of the building blocks needed for DNA synthesis, ultimately triggering cell death. This mechanism gives 5-FU broad activity across many cancer types, particularly those with high proliferative indices.

Botryoid-type embryonal rhabdomyosarcoma (RMS) of the vagina is an extremely rare pediatric mesenchymal tumor arising from primitive muscle precursor cells. The current standard of care for RMS centers on the VAC regimen (vincristine + actinomycin D + cyclophosphamide) or IVA, with 5-FU playing no established role. The TxGNN model's high prediction score (99.75%) most likely reflects knowledge graph propagation from the broader RMS disease node to Fluorouracil, rather than any direct disease-specific biological association.

While the general principle that antimetabolites suppress rapidly dividing cancer cells provides a superficial mechanistic rationale, this logic does not distinguish RMS from other tumor types, and no RMS-specific biomarker or pathway data supports 5-FU as a biologically meaningful candidate for this histology. This prediction should be regarded as a KG-derived signal and treated with caution.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for botryoid-type embryonal rhabdomyosarcoma of the vagina.

---

## Literature Evidence

Currently no related literature available for botryoid-type embryonal rhabdomyosarcoma of the vagina.

---

## Philippines Market Information

Fluorouracil currently has no registered products in the Philippine FDA registry. No authorization numbers, product names, dosage forms, or approved indications are available from this regulatory source.

---

## Cytotoxicity

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Conventional cytotoxic — Fluoropyrimidine class (antimetabolite) |
| Myelosuppression Risk | Moderate to High — neutropenia, thrombocytopenia, and anemia are common dose-dependent adverse effects; nadir typically occurs 9–14 days after administration |
| Emetogenicity Classification | Low to Moderate |
| Monitoring Items | CBC with differential and platelet count; liver function tests; renal function (creatinine, BUN); electrolytes; monitor for mucositis, hand-foot syndrome (palmar-plantar erythrodysesthesia), and diarrhea |
| Handling Protection | Classified as a hazardous drug — full cytotoxic handling precautions required (closed-system transfer devices, PPE including gloves and gown, preparation in a biological safety cabinet) |

---

## Safety Considerations

Please refer to the package insert for full safety information. No warnings, contraindications, or drug interaction data were retrievable from the current data sources.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is zero direct clinical trial or published literature evidence supporting the use of Fluorouracil specifically in botryoid-type embryonal rhabdomyosarcoma of the vagina. The TxGNN score of 99.75% reflects knowledge graph propagation through the RMS disease node — a well-known limitation of graph-based models where rare subtypes inherit high scores from their parent disease nodes — rather than any validated therapeutic relationship.

**To proceed, the following is needed:**
- Preclinical studies (in vitro cytotoxicity assays in RMS cell lines; ideally botryoid-subtype if available) to confirm whether 5-FU has meaningful activity against this histology
- Mechanistic investigation clarifying whether TS inhibition is a relevant vulnerability in embryonal RMS biology
- Broad literature review of 5-FU use in pediatric soft tissue sarcomas to assess any historical use data
- Clarification of Philippines registration status for Fluorouracil products to establish the regulatory baseline before any repurposing pathway is considered
- Safety gap remediation: obtain full package insert warnings, contraindications, and drug interaction profile from the Philippine FDA or originating regulatory agency

> **Disclaimer:** This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

